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OBJECTIVES The aim of this study was to evaluate percutaneous coronary intervention (PCI) in the
Assessment of the Safety and Efficacy of New Thrombolytic Regimens (ASSENT-3) trial.
BACKGROUND In the ASSENT-3 trial, co-therapy with abciximab (ABC) or enoxaparin (ENOX) reduced
ischemic complications after ST-elevation acute myocardial infarction treated with tenect-
eplase when compared with unfractionated heparin (UFH). The effect of these new
co-therapies on the results of PCI is unknown.
METHODS Clinical outcomes in patients who received co-therapy with ABC, ENOX, or UFH and
subsequently underwent an elective (n  1,064) or urgent (n  716) PCI in the ASSENT-3
trial were compared.
RESULTS No significant differences in clinical end points were observed in patients who underwent an
elective PCI. A non-significant trend toward fewer in-hospital myocardial re-infarctions was
seen with ABC and ENOX when compared with UFH (0.5% vs. 0.6% vs. 1.5%, respectively).
The incidence of bleeding complications was similar in the three treatment arms. Significantly
fewer ABC- and ENOX-treated patients needed urgent PCI compared with UFH (9.1% vs.
11.9% vs. 14.3%; p  0.0001), but outcomes in these patients were in general less favorable
(30-day mortality: 8.2% vs. 5.4% vs. 4.5%; 1-year mortality: 11.0% vs. 8.5% vs. 5.6%;
in-hospital re-infarction: 3.9% vs. 2.5% vs. 2.7%; major bleeding complications: 8.8% vs. 7.0%
vs. 3.4%). In pairwise comparisons with UFH, the higher one-year mortality and major
bleeding rates after ABC were statistically significant (p 0.045 and p 0.012, respectively).
CONCLUSIONS Clinical outcomes after elective PCI were similar with the three antithrombotic co-therapies
studied in ASSENT-3. Although fewer patients needed urgent PCI with ABC and ENOX,
clinical outcomes were less favorable in this selected population, especially with
ABC. (J Am Coll Cardiol 2003;42:1178–85) © 2003 by the American College of
Cardiology Foundation
Reperfusion therapy has been one of the major advances in
the treatment of acute myocardial infarction (AMI) since
See page 1186
the introduction of the coronary care unit. The combined
administration of a fibrinolytic agent, unfractionated hepa-
rin (UFH), and aspirin became the standard of care in the
late 1980s (1,2). Although significant improvements in
fibrinolytic therapy were made, substantial challenges re-
main (3–5). Optimal reperfusion of the infarct-related
epicardial coronary artery is achieved in only 50% to 60% of
the patients 60 to 90 min after initiation of treatment
(6–10). Other concerns are reperfusion at the tissue level,
recurrent ischemia or re-infarction, and bleeding complica-
tions (11,12). Newer co-therapies, including low-
molecular-weight heparin and platelet glycoprotein IIb/IIIa
inhibitors were tested in recent trials in conjunction with
fibrinolytics (13–15). Although no mortality benefit was
seen, these newer treatment regimens led to a consistent
reduction in ischemic complications, including re-infarction
and refractory ischemia. This benefit was partly counterbal-
anced by an increased rate of non-intracranial bleeding
complications.
A substantial proportion of patients with ST-elevation
AMI who receive thrombolytic therapy subsequently un-
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dergo a percutaneous coronary intervention (PCI). Unfrac-
tionated heparin has been the anticoagulant of choice
during PCI. As in acute coronary syndromes, newer anti-
coagulants (low-molecular-weight heparin or direct anti-
thrombins) and antiplatelet agents (platelet glycoprotein
IIb/IIIa inhibitors) emerged and have been proven to be safe
and perhaps even superior in elective and urgent PCI
(16–24). However, the effect of these newer treatment
regimens on the outcome of PCI performed after lytic
therapy is largely unknown.
We analyzed clinical outcomes in patients who under-
went PCI after lytic therapy in the Assessment of the Safety
and Efficacy of New Thrombolytic Regimens (ASSENT-3)
trial. In this trial, 6,095 patients with ST-elevation AMI of
6 h were randomly assigned to one of three regimens:
half-dose tenecteplase (TNK-tPA) with weight-adjusted
low-dose UFH and a 12-h infusion of abciximab (ABC),
full-dose TNK-tPA and enoxaparin (ENOX) for a maxi-
mum of seven days, or full-dose TNK-tPA with weight-
adjusted UFH for 48 h. The main results of this trial have
been published (15).
METHODS
Data management. Using the ASSENT-3 database, we
selected all patients who underwent urgent or elective PCI
during the initial hospitalization and evaluated them sepa-
rately. Elective PCI referred to a planned procedure and was
performed in 1,064 patients (17.5% of the total ASSENT-3
study population). A total of 716 patients (11.7%) under-
went an urgent PCI, defined as an ischemia-driven revas-
cularization before hospital discharge. Patients who under-
went both an urgent and an elective PCI (n  15) were
included in the analysis of urgent PCI. Outcomes of early
PCI (urgent or non-urgent), performed on the same day or
the day after thrombolytic treatment, were also assessed
separately. This group comprised 667 patients (11.0%).
These patients are of special interest because the treatment
effects of ABC and UFH have been thought to be most
pronounced during the first 24 to 48 h. Furthermore, most
efficacy end points of interest (death, re-infarction, refrac-
tory ischemia) occur early and could be influenced by early
intervention (25).
Analyzed data included the allocated trial medication,
time of randomization, death at 30 days, one-year mortality,
in-hospital myocardial re-infarction, in-hospital refractory
ischemia, in-hospital major and minor bleeds, puncture-
site-related bleeds as well as day of PCI, re-infarction, or
refractory ischemia. In the case of urgent PCI, reason for
urgency was also assessed (per protocol defined as myocar-
dial re-infarction, myocardial ischemia, or “others”). Data
were checked for completeness and for internal consistency
with source documents.
Definitions of efficacy and safety end points. We ana-
lyzed the composite end point of 30-day mortality, in-
hospital re-infarction, or in-hospital refractory ischemia
(efficacy end point) as well as the individual components of
the efficacy end point. Because one-year follow-up was
recently completed, one-year mortality data were also in-
cluded in our analysis. The incidence of in-hospital intra-
cranial hemorrhage (ICH), major non-cerebral bleeds, and
major and minor bleeds at the arterial puncture site (safety
end points) was also assessed. The same definitions for
re-infarction, refractory ischemia, and major versus minor
bleeding, as described in the main report of ASSENT-3,
were also used in our analysis (15).
Data analysis. Baseline characteristics were tabulated for
each treatment group. For binary and categorical variables,
differences between treatment groups were assessed using
the chi-square test. For continuous variables, an overall F
test was performed.
The end point data were analyzed using a proportional
hazards regression. To allow for the timing of the outcome
(before or after PCI) to be taken into account, PCI was
included as a time-dependent covariate (coded as 0 before
the performance of PCI, coded as 1 afterwards). In addition,
an interaction term between this time-dependent covariate
and treatment was also included in the model to allow for
different treatment effects before and after the performance
of a PCI. Furthermore, propensity scores (probability of
receiving treatment based on baseline characteristics) were
calculated for all patients and included in the model (26). By
including propensity scores in the model, it is hoped that
any imbalances in risk factors between the treatment groups
after the performance of a PCI will be reduced or removed.
For each of the three subgroups that were analyzed, a
propensity score analysis was performed, in which the
probability of receiving one of the three treatments was
modeled on the basis of patients’ baseline characteristics,
using a logistic regression. The models used to determine
the propensity scores included patients’ baseline character-
istics and their second-order interactions: gender, age,
weight, infarct location, previous myocardial infarction,
systolic and diastolic blood pressure, Killip class at entry,
time from symptom onset to treatment initiation, heart rate,
diabetes, previous coronary artery bypass surgery, previous
PCI, country (U.S./Europe/other), and randomization date.
Visual inspection of exploratory plots revealed that no
transformation of the continuous variables was necessary for
inclusion into the propensity model. For the urgent and
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early PCI groups, the concordance obtained with the
propensity model was good with C-statistics of 0.82 (UFH
vs. ENOX) and 0.83 (UFH vs. ABC) for the group of
patients with urgent PCI and C-statistics of 0.82 (UFH vs.
ENOX) and 0.85 (UFH vs. ABC) for the patients who
underwent an early PCI. For the subgroup of patients who
underwent an elective PCI, the C-statistics were 0.74 (UFH
vs. ENOX) and 0.73 (UFH vs. ABC). Then, based on the
obtained propensity scores, all patients were divided into
quintiles. For all subgroups studied, patient numbers and
baseline characteristics were tabulated by treatment group
within each of the obtained quintiles. The results indicated
that baseline characteristics were balanced within quintile
and that none of the covariates that were included in the
propensity model induced an inappropriate separation of the
treatments.
Based on the proportional hazards regression, pair wise
treatment comparisons between ENOX and UFH and
between ABC and UFH were calculated, together with
their corresponding 95% confidence interval. A chi-square
test was performed to assess the statistical significance of the
pairwise comparisons.
RESULTS
The distribution of patients who underwent an early,
elective, or urgent PCI in the three treatment arms is shown
in Table 1. Fewer patients in the ABC arm than in the
UFH arm underwent an urgent or early PCI. There was a
similar trend for urgent PCI with ENOX.
The baseline characteristics of the patients who under-
went an elective PCI were similar in the three treatment
arms (Table 2). Median time to revascularization was five
days in each group. The composite end point of 30-day
mortality, in-hospital myocardial re-infarction, or in-
hospital refractory ischemia, its individual components,
one-year mortality and non-intracranial bleeding complica-
tions in patients who underwent elective PCI are shown in
Figure 1.
There was one ICH in the UFH arm (0.30%) and one in
the ENOX arm (0.29%). No ICH was seen in the ABC
arm. No significant differences were observed between the
different treatment regimens. A trend towards fewer in-
hospital myocardial re-infarctions was seen in the ABC and
ENOX arms compared with the UFH arm, but statistical
significance was not reached. Low 30-day and one-year
mortality rates were observed after elective PCI, the lowest
in the ENOX arm. The incidences of in-hospital major
non-cerebral bleeds and arterial puncture-related major
bleeds were also similar in the three treatment arms. The
proportion of patients who received additional UFH during
PCI was similar in the three groups (77% for ABC, 79% for
ENOX, and 75% for UFH). Pair wise treatment compari-
sons with hazard ratios and corresponding 95% confidence
intervals for outcome after elective PCI are also shown in
Figure 1. Overall, there was a slightly more favorable
composite efficacy outcome with ENOX treatment, whereas
safety outcome was slightly better with ABC.
There was a significantly lower need for urgent PCI in
patients given ABC or ENOX when compared with UFH
(Table 1). Fewer early PCI were performed in the ABC arm
(Table 1). Of the urgent PCI performed, 75% were early
PCI. The baseline characteristics in patients who needed
urgent PCI or who underwent an early PCI are given in
Tables 3 and 4. Except for age in the urgent PCI analysis
and for time from onset of symptoms to TNK-tPA in the
early PCI analysis, baseline characteristics were similar.
Efficacy end points are summarized in Figures 2 and 3.
There was a trend towards reduced efficacy in the ABC arm,
with even a significantly higher one-year mortality when
compared with UFH.
The safety end points in the urgent and early PCI patient
population as well as the pairwise comparisons are shown in
Figures 2 and 3. One ICH was seen in each group (0.55%
for ABC, 0.41% for ENOX, and 0.34% for UFH) in urgent
PCI. Significantly more major, non-cerebral bleeding com-
plications were seen in the ABC group compared with the
Table 1. Distribution of Patients in the Different Subgroups
ABC
(n  2,009)
ENOX
(n  2,037)
UFH
(n  2,035) p Value*
Elective PCI 384 (19.1%) 348 (17.1%) 332 (16.3%) 0.0539
Urgent PCI 182 (9.1%) 242 (11.9%) 292 (14.3%)  0.0001
PCI on day 1
or 2
174 (8.7%) 232 (11.4%) 261 (12.8%)  0.0001
*p value: chi-square test for overall difference between treatment groups.
ABC  abciximab; ENOX  enoxaparin; PCI  percutancous coronary inter-
vention; UFH  unfractionated heparin.
Table 2. Baseline Characteristics in Patients With Elective PCI
Variable
ABC
(n  384)
ENOX
(n  348)
UFH
(n  332)
p
Value*
Age (yrs) 59  11† 59  12 60  12 0.60
Male gender (%) 73 77 75 0.59
Weight (kg) 82  18 80  16 80  16 0.09
Hypertension (%) 42 38 40 0.62
Diabetes mellitus (%) 14 15 15 0.82
Previous myocardial
infarction (%)
14 13 13 0.86
Previous PCI (%) 9 9 9 0.95
Previous CABG (%) 5 3 3 0.22
Anterior infarction (%) 34 34 36 0.76
Killip class I (%) 90 93 93 0.30
Systolic blood pressure
(mm Hg)
134  22 133  21 134  21 0.94
Heart rate (beats/min) 74  16 74  16 74  16 0.99
Hours from symptom
onset to TNK-tPA
3.0  1.5 2.8  1.5 2.9  1.4 0.20
*p value: chi-square test for binary and categorical variables, overall F-test for
continuous variables. †Continuous variables are mean  SD. Propensity scores: ABC
vs. UFH: 0.39  0.19 for the ABC group, 0.54  0.17 for the UFH group; ENOX
vs. UFH: 0.40  0.19 for the ENOX group, 0.58  0.19 for the UFH group.
ABC  abciximab; CABG  coronary artery bypass grafting; ENOX 
enoxaparin; PCI  percutaneous coronary intervention; TNK-tPA  tenecteplase;
UFH  unfractionated heparin.
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UFH group, whereas major bleeds at the arterial puncture
site were only slightly more frequent. There was a modest
increase in major, non-cerebral bleeds with ENOX com-
pared with UFH, mainly as a result of more puncture-
related bleeding complications. The proportion of patients
who received UFH during PCI was similar in the three
groups (71% for ABC, 68% for ENOX, and 71% for UFH).
Major bleeding rates were more frequent in patients who
needed urgent PCI compared with those in whom an
elective PCI was performed (Table 5).
DISCUSSION
A significant proportion of patients with ST-elevation AMI
who receive thrombolytic therapy subsequently undergo
urgent or elective PCI.
Figure 1. Clinical end points and pairwise treatment comparisons for outcome after elective PCI based on hazard ratios. In addition, 95% confidence
intervals (CI) and p values are presented. ABC abciximab; ENOX enoxaparin; UFH unfractionated heparin. Composite efficacy end point 30-day
mortality, in-hospital myocardial infarction, or in-hospital refractory ischemia. Squares  ENOX versus UFH; triangles  ABC versus UFH.
Table 3. Baseline Characteristics in Patients With Urgent PCI
Variable
ABC
(n  182)
ENOX
(n  242)
UFH
(n  292)
p
Value*
Age (yrs) 60  12† 61  10 58  12 0.03
Male gender (%) 75 82 79 0.22
Weight (kg) 83  17 84  17 83  16 0.36
Hypertension (%) 45 43 40 0.53
Diabetes mellitus (%) 16 20 17 0.42
Previous myocardial
infarction (%)
11 16 14 0.46
Previous PCI (%) 11 8 8 0.60
Previous CABG (%) 3 3 2 0.66
Anterior infarction (%) 41 41 43 0.80
Killip class I (%) 92 87 88 0.79
Systolic blood pressure
(mm Hg)
132  20 132  22 133  23 0.84
Heart rate (beats/min) 73  17 75  17 73  15 0.49
Hours from symptom
onset to TNK-tPA
2.7  1.3 2.5  1.3 2.6  1.3 0.10
*p value: chi-square test for binary and categorical variables, overall F-test for
continuous variables. †Continuous variables are mean  SD. Propensity scores: ABC
vs. UFH: 0.40  0.26 for the ABC group, 0.75  0.22 for the UFH group; ENOX
vs. UFH: 0.38  0.24 for the ENOX group, 0.69  0.22 for the UFH group.
Abbreviations as in Table 2.
Table 4. Baseline Characteristics in Patients With PCI on the
Same Day as or the Day After Fibrinolytic Treatment
Variable
ABC
(n  174)
ENOX
(n  232)
UFH
(n  261)
p
Value*
Age (yrs) 59  12† 59  11 57  12 0.14
Male gender (%) 75 84 82 0.07
Weight (kg) 84  17 85  16 84  17 0.56
Hypertension (%) 44 43 39 0.39
Diabetes mellitus (%) 17 17 16 0.90
Previous myocardial
infarction (%)
10 16 15 0.27
Previous PCI (%) 9 11 10 0.87
Previous CABG (%) 4 5 3 0.50
Anterior infarction (%) 43 38 44 0.43
Killip class I (%) 92 90 91 0.97
Systolic blood pressure
(mm Hg)
133  22 130  23 129  22 0.18
Heart rate (beats/min) 74  19 76  18 73  15 0.22
Hours from symptom
onset to TNK-tPA
2.7  1.3 2.3  1.2 2.5  1.3 0.02
*p value: chi-square test for binary and categorical variables, overall F-test for
continuous variables. †Continuous variables are mean  SD. Propensity scores: ABC
vs. UFH: 0.37  0.26 for the ABC group, 0.76  0.23 for the UFH group; ENOX
vs. UFH: 0.37  0.24 for the ENOX group, 0.68  0.22 for the UFH group.
Abbreviations as in Table 2.
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The aim of our study was to evaluate clinical outcomes in
patients who underwent PCI during initial hospitalization
in the ASSENT-3 trial. In light of the pharmacologic
properties attributable to ENOX, ease of administration
and proven safety and efficacy in non–ST-elevation acute
coronary syndromes and PCI, evaluation of the possible
Figure 2. Clinical end points and pairwise treatment comparisons for outcome after urgent PCI based on hazard ratios. In addition, 95% confidence
intervals (CI) and p values are presented. ABC abciximab; ENOX enoxaparin; UFH unfractionated heparin. Composite efficacy end point 30-day
mortality, in-hospital myocardial infarction, or in-hospital refractory ischemia. Squares  ENOX versus UFH; triangles  ABC versus UFH.
Figure 3. Clinical end points and pairwise treatment comparisons for outcome after early PCI based on hazard ratios. In addition, 95% confidence intervals
(CI) and p values are presented. ABC  abciximab; ENOX  enoxaparin; UFH  unfractionated heparin. Composite efficacy end point  30-day
mortality, in-hospital myocardial infarction, or in-hospital refractory ischemia. Squares  ENOX versus UFH; triangles  ABC versus UFH.
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benefit or harm of ENOX in PCI early after thrombolysis of
an ST-elevation AMI is important (16–18,27,28). Al-
though there is clear evidence that ABC reduces thrombotic
cardiac complications in patients undergoing PCI, it is not
known whether ABC is beneficial after PCI in patients with
ST-elevation AMI previously treated with reduced dose
thrombolytics (19–22).
No significant difference in the primary composite effi-
cacy end point or its components between the three treat-
ment regimens was seen in the population who underwent
elective PCI in ASSENT-3. Nevertheless, a trend towards
fewer in-hospital myocardial re-infarctions was seen in the
ENOX and ABC arms. Median time to elective revascu-
larization was rather long (five days after randomization).
Because per protocol ENOX was to be administered until
revascularization or discharge with a maximum of seven
days and because prolonged low-level platelet receptor
blockade may still be present up to 10 days after the
cessation of an ABC infusion, the antithrombotic effects of
ABC and ENOX may have been responsible for these
favorable outcomes, supporting the results of trials in
elective PCI (16,17,19,20,22).
In patients who underwent an urgent PCI during the
initial hospital stay in the ASSENT-3 trial, the overall low
event rates after the procedure make the interpretation of
differences in post-procedural outcome very hazardous. Our
analysis shows a somewhat higher incidence of the efficacy
end points after PCI in the ABC arm. More specifically,
there was a significantly higher one-year mortality and also
a slight excess in re-infarction. These worse outcomes are
difficult to understand because one would have expected
benefit in this regard from ABC (19,21,24). Although
baseline characteristics were similar in the three post-
randomization subgroups, differences in risk-profile (selec-
tion of a higher-risk population) could have played a role
despite our attempts to adjust for these imbalances.
An alternative explanation could be the observed differ-
ences as to the urgency of PCI. In ASSENT-3, total PCI
rates were similar in the three treatment arms with a
significantly lower need for urgent intervention in the ABC
arm and to a lesser extent in the ENOX arm and a
borderline significant excess of elective PCI in the ABC
arm. Patient characteristics (and hence probably lesion
characteristics and extent of disease) were similar in the
three treatment groups in ASSENT-3 (15). Because differ-
ences in urgency for revascularization are likely to be a direct
treatment effect, patients with similar lesion complexity
could potentially have been shifted from urgent to elective
PCI or even medical therapy, as a consequence of the
plaque-stabilizing characteristics of ABC. This could have
resulted in a concentration of very complex “ABC-resistant”
lesions in a smaller group of patients undergoing urgent
revascularization and a selection of “ABC-stabilized” but
complex lesions in the group of patients undergoing an
elective intervention. Percutaneous coronary intervention in
these patients with complex lesions might have a worse
prognosis, and this could explain in part the higher mortal-
ity rates. On the other hand, some “ABC-stabilized” pa-
tients who were treated medically could have benefited from
a PCI, preventing late re-infarction and death.
Safety of the new antithrombotic co-therapies was not an
issue after elective PCI. The rates of in-hospital non-
cerebral major bleeds as well as puncture-related bleeds were
low and similar in the three treatment arms. These results
are in accordance with other recent trials (16,17,20,22). The
time to elective PCI in ASSENT-3 was long (5 days),
which may partly explain the low rates of major bleedings at
the puncture site.
An excess of major bleeds was observed in patients who
needed urgent PCI compared with those who underwent an
elective PCI (Table 5). This excess was small in the UFH
group but larger in the ABC and ENOX groups. When
compared with UFH, the incidence of major, non-cerebral
bleeds in patients undergoing urgent PCI was significantly
higher with ABC, whereas there was a modest increase in
patients treated with ENOX. Overall, puncture-related
bleeds (major and minor) were similar in the three arms.
Nevertheless, the incidence of major puncture-related
bleeds was higher in the ENOX arm. It is unlikely that this
difference could be attributed to additional administration
of UFH during the procedure, because the proportion of
Table 5. Bleeding Episodes After Urgent PCI Compared With Elective PCI and No PCI in
ASSENT-3 Population
End Points
Urgent PCI
ASSENT-3
Elective PCI
ASSENT-3
No PCI
ASSENT-3
In-hospital major bleeds (excluding ICH)
UFH 10/292 (3.4%) 6/332 (1.8%) 24/1411 (1.7%)
ENOX 17/242 (7.0%) 6/348 (1.7%) 38/1446 (2.6%)
ABC 16/182 (8.8%) 4/384 (1.0%) 57/1443 (4.0%)
Puncture-related bleeds
UFH 56/292 (19.2%) 34/332 (10.2%)
ENOX 55/242 (22.7%) 30/348 (8.6%)
ABC 34/182 (18.7%) 33/384 (8.6%)
ABC  abciximab; ASSENT-3  Assessment of the Safety and Efficacy of New Thrombolytic Regimens; ENOX 
enoxaparin; ICH  intracranial hemorrhage; PCI  percutaneous coronary intervention; UFH  unfractionated heparin.
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patients who received additional UFH during PCI was
similar in the three groups.
Bleeding sites differed among the three treatment arms:
one-fourth of the major bleeds occurred at the arterial
puncture site in the ABC arm, in contrast with one-half and
almost two-thirds in the UFH and ENOX arms, respec-
tively (Fig. 2). These observations are in line with those of
the Global Use of Strategies To open Occluded coronary
arteries (GUSTO V) trial (14). No single bleeding site could
explain the relatively higher proportion of non-puncture-
related major bleeding episodes in the ABC arm. New trials
of facilitated PCI will evaluate the safety of different
pre-PCI pharmacologic reperfusion regimens.
Our study has several limitations. Because this was a post
hoc analysis, caution is needed when interpreting differences
between treatment groups, because the performance of PCI
could have been influenced by the study treatments. In
addition, interactions between study treatment and PCI can
further obscure the study treatment effect. We tried to
address some of these issues by analyzing data using a
proportional hazards regression that included the interac-
tion between occurrence of PCI and treatment, in which
PCI was included as a time-dependent covariate, and by
calculating propensity scores in order to avoid or to reduce
imbalances between treatment groups after the performance
of a PCI. It should be kept in mind that even when taking
the above measures, it is impossible to ascertain the true
effect of the study treatment in the group of patients who
underwent a PCI. No adjustments for multiplicity were
made, and false positive results can therefore not be ex-
cluded. On the other hand, event rates were low, and true
differences might have been missed because of the small
sample size.
CONCLUSIONS
Clinical outcomes in patients with an ST-elevation AMI
undergoing an elective PCI after treatment with TNK-tPA
were similar in the three treatment arms studied in
ASSENT-3, and no excess of bleeding complications was
observed.
Although fewer patients needed urgent PCI after co-
therapy with ABC and ENOX, clinical outcomes were less
favorable in this selected population, especially with ABC.
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